The company was listed in 1998, and its main business is R&D, manufacturing, sales and consulting services for blood products. After two major asset restructuring in 2010 and 2017, it became a specialized blood products operating company of China Biotechnology Co., Ltd. The company's main business is to develop and produce blood products using healthy human plasma or healthy human plasma that has undergone specific immunization as raw materials and uses genetic recombination technology to develop and produce blood products business. The company's main products include human blood albumin, intravenous human immunoglobulin (pH4), tetanus immunoglobulin, rabies patient immunoglobulin, human hepatitis B human immunoglobulin, freeze-dried intravenous hepatitis B human immunoglobulin (pH4), human immunoglobulin, histamine human immunoglobulin, human thrombin complex, human clotting factor VIII, human fibrinogen, etc. Corporate honors: 2017 High-tech Enterprise, Sichuan Famous Brand Product Title, Beijing Biomedical Industry Leap Development Project (G20 Project), Advanced Standard Research Unit for the 2010 Edition of the Chinese Pharmacopeia, Innovative Enterprise in Zhongguancun National Independent Innovation Demonstration Zone, etc.
No Data